The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

Summary CD137 (4-1BB)-activating receptor represents a promising cancer
immunotherapeutic target. Yet, the cellular program driven by CD137 and its role in cancer …

The intact antibody of human immunoglobulin (IgG) is composed of the fragment for antigen
binding (Fab) and the crystallizable fragment (Fc) for binding of Fcγ receptors. Among the …

The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …

The clinical development of 4–1BB agonists for cancer immunotherapy has raised
substantial interest during the past decade. The first generation of 4–1BB agonistic …

Twenty-five years ago, we reported that agonist anti-CD137 monoclonal antibodies
eradicated transplanted mouse tumors because of enhanced CD8+ T-cell antitumor …

The leukocyte Fcγ receptor (FcγR)-mediated response is important for the efficacy of
therapeutic antibodies; however, little is known about the role of FcγRs in other cell types …